Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. The company's plasma fractionation capacity is currently at 22 million liters per year, with the aim of reaching 26 million by 2026, as part of efforts to meet growing demand for plasma-derived medicines. Strategic positioning centers on expanding production capacity and therapeutic innovation in plasma-derived solutions.
Cyborg Score Rationale
Grifols has reported record revenue and higher profitability, while rating agencies and lenders have acknowledged progress in reducing leverage and strengthening liquidity. However, the capital structure remains a key risk factor, with elevated leverage, sensitivity to refinancing costs, and sector-wide regulatory or pricing developments.
Top Insights
Record revenue and profitability in 2025 with improving operational execution amid ongoing deleveraging efforts
Plasma capacity expansion targeting 26 million liters annually by 2026 to capture growing demand for plasma-derived therapies
Recent FDA approval for Fesilty launch in H1 2026, demonstrating continued pipeline advancement
Key leverage and refinancing risk remain focal points for investor scrutiny and analyst ratings
Named Competitors
CSL Behring — Global plasma-derived biotherapeutics manufacturer
BioMarin — Specialized biopharmaceuticals for rare genetic diseases
United Therapeutics — Specialty biopharmaceutical company for critical care
Alnylam — RNAi therapeutics for genetic diseases
Recent Developments
(February 2026) FDA approval secured for Fesilty product launch in US during first half of 2026
(January 2026) Board restructure with changes to secretary and vice-secretary roles to improve governance
(December 2025) JP Morgan reduced 12-month price target to $10 citing ongoing reassessment of leverage and cash generation
(December 2024) Acquisition of 14 plasma collection centers from Immunotek in corporate asset purchase
Open the full interactive Grifols, S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.